Search for a trial

Markers of Efficacy of Xolair (Omalizumab) in Chronic Spontaneous Urticaria

To relate the reduction of inflammatory characteristics in skin and in peripheral blood to clinical efficacy in patients with CSU. Major focusses of this study are the (early) effects on basophils and other Fc*RI-bearing leukocytes before, during,…

Prevalence of latex allergy among operating room employees in the Netherlands

Research questions:What is the current prevalence of latex allergy among operating room employees from Erasmus Medical Centre, Rotterdam? Is the sensitisation prevalence significantly lower compared to the prevalence before introducing non powdered…

Efficacy and safety of canakinumab in Schnitzler syndrome

Primary: To determine whether IL-1 inhibition by Canakinumab is efficacious in treatment of Schnitzler syndrome.Secondary:1. To assess the effect of canakinumab on Schnitzler syndrome (clinical signs/symptoms and inflammatory biomarkers C-reactive…

Development of the basophil activation test.

The aim of this study is to develop and validate the basophil activation test by flow cytometry in our hospital as an extra diagnostic procedure for patients, who can not be diagnosed with existing tests or who have the risk of developing…

Food allergy to soy:
"Characteristics of soy allergy profiles in relation to the severity of the symptoms after ingestion."

To investigate causes and predictors for primary or secondary allergy profiles for soymilk

A randomized, double-blind, placebo-controlled exploratory trial to evaluate a one-week oral treatment with R129160 (60 mg o.d.) in patients with chronic idiopathic urticaria

Explore the efficacy, safety and tolerability of oral R129160, 60 mg o.d. in patients with chronic idiopathic urticaria

An open-label, multicenter, extension study to evaluate the long-term safety and tolerability of LOU064 in eligible subjects with CSU who have participated in preceding studies with LOU064

To assess the long-term safety and tolerability of LOU064 in patients with CSU who have participated in preceding studies with LOU064.

A Randomized, Double Blind, Placebo Controlled, Phase 2a Study to Assess the Clinical Efficacy of ISIS 721744, a Second Generation Ligand Conjugated Antisense Inhibitor of Prekallikrein, in Patients with Hereditary Angioedema

The primary objective of the study is to evaluate the clinical efficacy of antisense inhibitor of prekallikrein (ISIS 721744) in patients with hereditary angioedema (HAE) type 1 (HAE 1), HAE type 2 (HAE 2), or HAE with normal C1-inhibitor (C1-INH).…

Conestat alfa as prophylactic treatment for idiopathic non-histaminergic acquired angioedema

The primary objective of this exploratory study is to test if prophylactic use of conestat alfa decreases the frequency of angioedema attacks in patients with InH-AAE. As secondary objectives, effects on disease severity, quality of life and drug…

A multicenter, randomized, double-blind, placebocontrolled Phase 2b dose-finding study to investigate the efficacy, safety and tolerability of LOU064 in adult chronic spontaneous urticaria patients inadequately controlled by H1-antihistamines

The primary objective of this study is to characterize the dose-response relationship of LOU064 administered once or twice daily in subjects with CSU with respect to change from baseline in UAS7 at Week 4.

Brain activity in Urticaria Factitia using neurophysiological imaging

The aim of this study is to investigate alterations in brain activity in UF patients by detecting and characterizing MEG changes, using network theory.

A multi-center, randomized, double-blind, placebo controlled study of ligelizumab (QGE031) in the treatment of Chronic Inducible Urticaria (CINDU) in adolescents and adults inadequately controlled by H1-antihistamines

The purpose of this study is to establish efficacy and safety of ligelizumab (QGE031) versus placebo in participants with chronic inducible urticaria who remain symptomatic despite treatment with H1 antihistamine.

An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of
Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic
Angioedema with Normal C1-Inhibitor (C1-INH)

Primary: To evaluate the long-term safety of repeated subcutaneous(SC) administrations of lanadelumab in adolescents and adults with nonhistaminergicangioedema with normal C1-INH

A multi-center, randomized, double-blind, active and placebo-controlled study to investigate the efficacy and safety of ligelizumab (QGE031) in the treatment of Chronic Spontaneous Urticaria (CSU) in adolescents and adults inadequately controlled with H1-antihistamines

The purpose of this study is to establish efficacy and safety of ligelizumab in adolescent and adult subjects with CSU who remain symptomatic despite standard of care treatment by demonstrating better efficacy over omalizumab.

A randomized, double-blind, placebo-controlled, multi-center, dose-ranging Phase 2 study of rilzabrutinib followed by an open-label extension phase in patients with moderate-to-severe chronic spontaneous urticaria (CSU) who remain symptomatic despite the use of H1 antihistamine treatment

The purpose of the study is to evaluate how effective rilzabrutinib is and how safe it is, in reducing the signs and symptoms in patients with chronic spontaneous urticaria (CSU), who continue to have symptoms despite the use of H1-antihistamines (…

A multi-center, double-blinded and open-label extension study to evaluate the efficacy and safety of ligelizumab as retreatment, self-administered therapy and monotherapy in Chronic Spontaneous Urticaria patients who completed studies CQGE031C2302, CQGE031C2303, CQGE031C2202 or CQGE031C1301

The purpose of the study is to establish the efficacy and safety of ligelizumab in treating adult and adolescent subjects with chronic spontaneous urticaria. This study also looks how:• further treatment of ligelizumab works following ligelizumab or…

A Phase 3 Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ISIS 721744 in Patients with Hereditary Angioedema (HAE)

Primary objective: The primary objective of the study is to evaluate the clinical efficacy of ISIS 721744 in patients with hereditary angioedema (HAE).Secondary objective: Evaluate the effects of ISIS 721744 on the quality and pattern of HAE attacks…

An Open-Label Extension Study of ISIS 721744 in Patients with Hereditary Angioedema

This study has been transitioned to CTIS with ID 2024-517249-15-00 check the CTIS register for the current data. Primary Objective:To evaluate the safety of extended dosing, and alternative dosing and/or dose frequency with ISIS 721744 in patients…

An Open-Label, Long Term Safety and Efficacy Study of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)

This study has been transitioned to CTIS with ID 2023-509201-77-00 check the CTIS register for the current data. Primary ObjectiveTo evaluate the safety of long-term dosing with donidalorsen in patients with HAE. Secondary ObjectivesTo evaluate the…

A virtual, decentralised observational follow-up study investigating feeding patterns in infancy and the associated parent-reported allergic manifestations, allergies and infections in childhood.

Given the worldwide-observed rapid increase in the prevalence of allergic diseases, it is likely that environmental risk factors, including geographic area and lifestyle factors play a substantial role in the development of allergies and other…